Cancer screening

AACR Annual Meeting 2021: AnchorDx Unveils High-Performance Blood Test for Gastric Cancer Screening

Retrieved on: 
Monday, April 19, 2021

b"GUANGZHOU,China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results.

Key Points: 
  • b"GUANGZHOU,China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results.
  • In addition to superior sensitivity and specificity features, Aurora 2.0 retains its original advantages such as low cost and short turnaround time.
  • In China, the incidence and mortality of gastric cancer rank second (10.5%) and third (12.4%), respectively.
  • In addition, AnchorDxhas a proprietarybig data and artificial intelligence platform designed for early lung cancer screening, diagnosis, and treatment.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/aacr-annual-meeting-2021-anchord...\n"

Adventist Health, OSF HealthCare Use CancerIQ to Prioritize Patients for Preventive Cancer Screenings

Retrieved on: 
Thursday, April 15, 2021

"That drop off may have delayed tens of thousands of breast cancer diagnoses," said Feyi Olopade Ayodele, CEO, CancerIQ.

Key Points: 
  • "That drop off may have delayed tens of thousands of breast cancer diagnoses," said Feyi Olopade Ayodele, CEO, CancerIQ.
  • "Instead of leaving huge holes in preventive care, we found virtual care, supported by CancerIQ, could help us ensure high-risk patients received appropriate care throughout the pandemic.
  • Even during lock down, we were able to identify and justify screenings for high-risk patients, which enabled us to diagnose multiple women with breast cancer while their disease was still curable.
  • By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers providers with the genetic expertise to prevent cancer or catch it early.

RSNA: Lung Cancer Screening Predicts Risk of Death from Heart Disease

Retrieved on: 
Thursday, April 15, 2021

b'OAK BROOK, Ill., April 15, 2021 /PRNewswire-PRWeb/ --A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a study published in Radiology: Cardiothoracic Imaging .\nCardiovascular disease is the leading cause of mortality worldwide.

Key Points: 
  • b'OAK BROOK, Ill., April 15, 2021 /PRNewswire-PRWeb/ --A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a study published in Radiology: Cardiothoracic Imaging .\nCardiovascular disease is the leading cause of mortality worldwide.
  • It even outpaces lung cancer as the leading cause of death in heavy smokers.\nLow-dose CT lung scans are used to screen for lung cancer in high-risk people such as heavy smokers.
  • These CT scans also provide an opportunity to screen for cardiovascular disease by extracting information about calcification in the heart and aorta.
  • The Society is based in Oak Brook, Ill. ( RSNA.org )\nFor patient-friendly information on lung cancer screening, visit RadiologyInfo.org .\nLinda Brooks, Radiological Society of North Aurora, 630-590-7762, [email protected]\n'

Consolidate Your Health Records with Therap's "Life Records for Families and Individuals" Electronic Health Record (EHR) System

Retrieved on: 
Tuesday, April 13, 2021

b"WATERBURY, Conn., April 13, 2021 /PRNewswire/ -- As medical practices, clinics, and hospitals become more specialized it can be difficult to see the same doctor on a regular basis and even harder to manage your medical records.

Key Points: 
  • b"WATERBURY, Conn., April 13, 2021 /PRNewswire/ -- As medical practices, clinics, and hospitals become more specialized it can be difficult to see the same doctor on a regular basis and even harder to manage your medical records.
  • A clinic may hand you a record of a colonoscopy, electrocardiogram, or lab work as you walk out the door but where do you keep it and how big a folder do you lug to your next appointment.
  • The power and sophistication of Therap's Industry leading EHR is now available and affordable for individuals and families to maintain your medical history and, if necessary, the medical histories of your family in an easily accessible web based EHR system.\nTherap began developing and marketing its EHR in 2003 for human services organizations.
  • Therap's system is web based, inexpensive, transparent, and full featured.

Say Hello to our Square Care Breast Imaging Program

Retrieved on: 
Tuesday, April 13, 2021

b'NEW HYDE PARK, N.Y., April 13, 2021 /PRNewswire-PRWeb/ --Square Care Medical Group, a multi-specialty group with a focus on Women\'s Healthcare, is excited to announce its first ancillary service as it opens New Hyde Park Mammography.

Key Points: 
  • b'NEW HYDE PARK, N.Y., April 13, 2021 /PRNewswire-PRWeb/ --Square Care Medical Group, a multi-specialty group with a focus on Women\'s Healthcare, is excited to announce its first ancillary service as it opens New Hyde Park Mammography.
  • The new suite is located within the offices of Dr. Frank Dolisi and, in conjunction with Mt.
  • Sinai Radiology, will deliver a high caliber breast imaging and mammography service to our patients.
  • "\nAll patients of our Square Care Breast Imaging Program should expect to receive superb care, and known for:\nHere is the information for the Square Care Breast Imaging Program and Making Appointments:\n'

BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes

Retrieved on: 
Tuesday, April 13, 2021

The collaboration will support the ACBTB\'s mission to improve the treatment outcomes of patients with breast cancer.

Key Points: 
  • The collaboration will support the ACBTB\'s mission to improve the treatment outcomes of patients with breast cancer.
  • We welcome ABCTB to our global coalition of data partners, enabling deep data access that can improve outcomes for affected patients.
  • "\nProfessor Christine Clarke, Emeritus Professor, The University of Sydney, Distinguished Scientist, The Westmead Institute for Medical Research, and Chair, the Australian Breast Cancer Tissue Bank, said, "Our collaboration with BC Platforms is a new pathway to facilitate worldwide access to the ABCTB resource.
  • For more information, please visit www.bcplatforms.com or follow us on Linkedin @BC Platforms .\nThe Australian Breast Cancer Tissue Bank (ABCTB) was created to provide an open-access resource of breast cancer biospecimens and clinical data to support breast cancer research.\nThis was achieved through the support of women with breast cancer, who consented for ABCTB to securely store their samples and data; and through the participation of a collaborative network of cancer clinicians and researchers.

BC Platforms Partners with Australian Tissue Bank (ABCTB) to Improve Breast Cancer Treatment Outcomes

Retrieved on: 
Tuesday, April 13, 2021

The collaboration will support the ACBTB\'s mission to improve the treatment outcomes of patients with breast cancer.

Key Points: 
  • The collaboration will support the ACBTB\'s mission to improve the treatment outcomes of patients with breast cancer.
  • We welcome ABCTB to our global coalition of data partners, enabling deep data access that can improve outcomes for affected patients.
  • "\nProfessor Christine Clarke, Emeritus Professor, The University of Sydney, Distinguished Scientist, The Westmead Institute for Medical Research, and Chair, the Australian Breast Cancer Tissue Bank, said, "Our collaboration with BC Platforms is a new pathway to facilitate worldwide access to the ABCTB resource.
  • For more information, please visit www.bcplatforms.com or follow us on Linkedin @BC Platforms .\nThe Australian Breast Cancer Tissue Bank (ABCTB) was created to provide an open-access resource of breast cancer biospecimens and clinical data to support breast cancer research.\nThis was achieved through the support of women with breast cancer, who consented for ABCTB to securely store their samples and data; and through the participation of a collaborative network of cancer clinicians and researchers.

U.S. FDA Grants De Novo Clearance for First and Only Artificial Intelligence System for Colonoscopy; Medtronic Launches GI Genius™ Intelligent Endoscopy Module

Retrieved on: 
Monday, April 12, 2021

The GI Genius module is the first and only commercially available computer-aided detection (CADe) system using artificial intelligence (AI) to identify colorectal polyps.

Key Points: 
  • The GI Genius module is the first and only commercially available computer-aided detection (CADe) system using artificial intelligence (AI) to identify colorectal polyps.
  • With GI Genius we can tap into the potential of artificial intelligence approaches to increase detection rates.
  • "With FDA de novo clearance for the GI Genius and its AI capabilities, we expect to enhance and improve colonoscopies and polyp detection.
  • The GI Genius intelligent endoscopy module received de novo clearance from the U.S. FDA on April 9, 2021.

Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

Retrieved on: 
Monday, April 12, 2021

The device is the first of its kind to obtain the FDA approval through the De Novo application.

Key Points: 
  • The device is the first of its kind to obtain the FDA approval through the De Novo application.
  • ), where detection rates improved very significantly with GI Genius technology versus standard colonoscopy, regardless of skill level or endoscope used.
  • The first ever approval of an artificial intelligence device for lesion detection in colonoscopies further strengthens Cosmo\'s commitment to fight colorectal cancer.
  • We are extremely pleased and very optimistic about the impact the GI Genius intelligent endoscopy module will have on the US patient population undergoing colonoscopy.

Cosmo announces FDA approval of GI Genius™ intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy

Retrieved on: 
Monday, April 12, 2021

The device is the first of its kind to obtain the FDA approval through the De Novo application.

Key Points: 
  • The device is the first of its kind to obtain the FDA approval through the De Novo application.
  • ), where detection rates improved very significantly with GI Genius technology versus standard colonoscopy, regardless of skill level or endoscope used.
  • The first ever approval of an artificial intelligence device for lesion detection in colonoscopies further strengthens Cosmo\'s commitment to fight colorectal cancer.
  • We are extremely pleased and very optimistic about the impact the GI Genius intelligent endoscopy module will have on the US patient population undergoing colonoscopy.